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Abstract 
 
 Neuromodulators such as serotonin, oxytocin, and testosterone play an 
important role in social behavior. Studies examining the effects of these 
neuromodulators and others on social cognition and behavior, and their neural 
underpinnings, are becoming increasingly common. Here, we provide an 
overview of methodological considerations for those wishing to evaluate or 
conduct empirical studies of neuromodulation in social neuroscience. 
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Introduction 
 One of social psychology’s most important contributions is the notion that 
situations are powerful determinants of human behavior (Ross & Nisbett, 1991). 
Methodological advances in social and affective neuroscience are beginning to 
provide us with tools for discovering how.  Brains are sensitive to the surrounding 
environment, and one mechanism through which environments shape brains is 
by influencing the function of neuromodulators- chemicals that modify neuronal 
dynamics, excitability, and synaptic function. Neuromodulators include 
neurotransmitters (e.g., serotonin, noradrenaline, acetylcholine, and dopamine) 
as well as hormones (e.g., testosterone, oxytocin, vasopressin). These chemicals 
may serve to prepare organisms to interact optimally with the environment, 
shaping behavior to fit the current context in an adaptive manner. Activation of 
one or more of these chemical systems is an efficient way to alter the 
computational properties of neural networks at a global level (Robbins & Arnsten, 
2009). 
 Recent work has begun to examine how manipulating neuromodulators 
influences social cognitions and behaviors such as trust (Kosfeld, et al., 2005), 
punishment (Crockett et al., 2013; Crockett et al., 2008), moral judgment 
(Crockett, et al., 2010a), conformity (Campbell-Meiklejohn et al., 2012; Stallen, et 
al., 2012), and empathy (Hurlemann et al., 2010).  The effects of specific 
neuromodulators on social behavior have been reviewed elsewhere 
(Crockett & Fehr, in press; Siegel & Crockett, in press; Insel, 2010; 
Eisenegger et al., 2011). Here, we provide a primer for conducting and 
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evaluating empirical studies with neuromodulatory tools, highlighting 
methodological issues that are particularly salient in the context of studying social 
behavior. This topic is important for advancing social, cognitive and 
affective neuroscience for at least three reasons. First, animal research 
provides strong evidence that neuromodulators play a crucial role in a 
range of important social behaviors, including affiliation, aggression, and 
social dominance (Insel, 2010); neurobiological models of human social 
behavior will be incomplete without a detailed understanding of 
neuromodulator effects. Second, the pharmacological techniques used to 
study neuromodulator function in humans often produce subjective effects 
on mood and cognitive factors like attention and executive control. As 
mood, attention and executive control can exert independent influences on 
social behavior (Lieberman, 2003; Strack & Deutsch, 2004), designing 
experiments to identify selective effects of neuromodulators on social 
behavior requires care and consideration. Finally, psychological disorders 
are often characterized by dysfunctional social cognition as well as 
abnormal neuromodulator function (Kishida et al., 2010); research 
examining how neuromodulators influence healthy social cognition may 
pave the way for pharmacological therapies to ameliorate social 
disturbances in psychological disorders. 
 
Methods for manipulating neuromodulators 
Direct administration 
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 Direct oral or intravenous administration of neuromodulators (e.g., 
serotonin, norepinephrine and dopamine) is not generally possible, because 
most of these molecules cannot cross the semi-permeable separation that 
prevents materials in the bloodstream from entering the brain (called the “blood-
brain barrier”). For some neuropeptides (e.g., oxytocin and vasopressin), it may 
be possible to administer the compounds through the nasal passages, which 
bypass the blood-brain barrier; the majority of studies examining how 
oxytocin affects social behavior have used intranasal administration 
(Veening & Olivier, 2013). However, it remains unclear how intra-nasally 
administered neuromodulators enter the brain and reach the appropriate receptor 
sites (Churchland & Winkielman, 2012; Veening & Olivier, 2013). The hormones 
testosterone and estradiol, which do cross the blood-brain barrier, can be 
administered orally (Bos et al., 2011). 
 
Precursor manipulation 
 Neuromodulator levels can be influenced by manipulating their chemical 
precursors, which can be amino acids or other molecules that are able to cross 
the blood-brain barrier. Neuromodulator production can sometimes be 
enhanced by increasing the availability of precursor via pharmacological or 
dietary supplementation, or impaired by decreasing the availability of precursor 
via dietary depletion.  
 Dietary depletion of precursor results in a reversible, partial global reduction 
in brain neurotransmitter levels. In the precursor depletion procedure, subjects 
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ingest an amino acid load (usually in liquid or pill form) that does not contain 
the precursor amino acid but does include other large neutral amino acids 
(LNAAs). The influx of amino acids lowers the ratio of precursor to other LNAAs. 
Since the precursor competes with other LNAAs to enter the brain through the 
blood-brain barrier, lowering the precursor:LNAA ratio almost completely halts 
precursor transport into the brain (Booij et al., 2003).  
 There are two techniques for dietary enhancement of neuromodulator 
precursors. The first, called supplementation, involves administering a 
smaller dose of the precursor over several days or weeks. The second, 
called loading, involves administering a large acute dose of the precursor. 
Supplementation and loading are able to enhance neuromodulator 
production when the enzyme that produces the neuromodulator is not 
normally saturated. For instance, serotonin production can be enhanced by 
supplementation or loading of its precursor, the amino acid tryptophan. 
This is because the rate-limiting enzyme that converts tryptophan to 
serotonin, tryptophan hydroxylase, is not normally saturated (Silber & 
Schmitt, 2010). 
 Further examples of precursor manipulation include tryptophan depletion 
(impairs serotonin production), tyrosine depletion (impairs noradrenaline and 
dopamine production), and L-DOPA administration (enhances dopamine 
production). 
 
Receptor agonists & antagonists 
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 Neuromodulators work by binding to different kinds of receptors. 
There are many different types of receptors for each neuromodulator 
system, and different receptor types can have different effects on neuronal 
function when activated. For example, dopamine D1 and D2 receptors can 
have opposing effects on long-term potentiation and neuronal excitability 
(reviewed in Frank, 2005). The distribution of different receptor types can 
vary across the brain; so for instance, D1 and D2 receptors are found in 
roughly equal prop rtions in the striatum, whereas D1 receptors outnumber 
D2 receptors in much of the prefrontal cortex (Hall et al., 1994).  The 
consequence of this neuronal architecture is that neuromodulators, when 
released, can have different effects in different brain regions according to 
the type of receptor activated. Some pharmacological agents directly stimulate 
or block neuromodulator receptors. These agents can be highly selective 
(targeting only a specific receptor sub-type) or less so (targeting a general class 
of receptors and binding to multiple receptor sub-types). Antagonists bind to the 
receptor and block the actions of the endogenous neuromodulator, thus impairing 
neuromodulator function. Agonists bind to the receptor and mimic the actions of 
the endogenous neuromodulator. When agonists bind to post-synaptic receptors, 
their net effect is to increase neuromodulator function. However, agonists and 
antagonists can also influence neuromodulator function by binding to special 
receptors called autoreceptors. Autoreceptors are located on the neurons that 
produce and release neurotransmitters. When activated, autoreceptors inhibit 
synthesis and release of neurotransmitter. This is a negative feedback 
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mechanism designed to keep neurotransmitter release in homeostatic balance. 
Meanwhile, antagonism of autoreceptors can stimulate neurotransmitter 
synthesis and release by blocking negative feedback brought on by endogenous 
neurotransmitter. Thus, when they bind to autoreceptors, agonists have the net 
effect of decreasing neuromodulator function, while antagonists have the net 
effect of increasing neuromodulator function. The effects of agonists and 
antagonists on neuromodulator function therefore depend on whether they 
activate pre-synaptic or post-synaptic receptors. Examples of such drugs include 
haloperidol (antagonist for multiple dopamine receptors), sulpiride 
(antagonist for dopamine D2 receptors), pramipexole (agonist for dopamine 
D2 receptors), bromocriptine (agonist for dopamine D1 and D2 receptors), and 
propranolol (antagonist for noradrenaline beta receptors). 
 
Re-uptake inhibition 
 Selective re-uptake inhibitors increase the concentration of neuromodulator 
in the synapse by blocking its presynaptic re-uptake. Re-uptake inhibitors work 
by blocking the presynaptic active transport mechanism in the transporter 
protein, located on the cell membrane, that is responsible for taking up 
neurotransmitter from the synapse after its release. Consequently, the action 
of the neuromodulator on postsynaptic receptors is prolonged. Examples of re-
uptake inhibitors include citalopram, paroxetine and fluoxetine (selective 
serotonin re-uptake inhibitors, or SSRIs); atomoxetine and reboxetine (selective 
noradrenaline re-uptake inhibitors, or SNRIs); and methylphenidate (a dopamine 
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re-uptake inhibitor).  
 There is some evidence that acute administration of re-uptake 
inhibitors can under certain conditions lead to a net decrease in the release 
of neuromodulator. This is thought to be caused by the down-regulating 
effects of pre-synaptic autoreceptor activation. For instance, a recent study 
showed that a 10mg intravenous dose of citalopram led to a net decrease 
in endogenous serotonin release by the raphé nuclei, brought on by 
enhanced serotonergic transmission within the raphé nuclei (Selvaraj et al., 
2012). Studies in animals suggest that the dosage used is likely to 
influence whether acute SSRI administration enhances or reduces 5-HT 
neurotransmission, with lower doses reducing 5-HT neurotransmission (via 
autoreceptor negative feedback) and higher doses enhancing 5-HT 
neurotransmission (Bari et al., 2010).  However, further research is needed 
to specify the effects of reuptake-inhibitor dosages on neurotransmission 
in human subjects.  
 
Metabolic enzyme inhibitors 
 The synaptic actions of neurotransmitters can be prolonged by 
pharmacologically restraining the metabolic enzymes that break down 
neurotransmitters after they’re released. One example is galantamine, which 
inhibits the enzyme that degrades acetylcholine, thus prolonging cholinergic 
actions in the brain. 
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 9 
Practical issues in behavioral psychopharmacology 
Placebo and blinding issues 
 One advantage of using pharmacological manipulations to study the 
neurobiology of social behavior is that such manipulations can establish causal 
mechanisms, as long as the experiment is properly designed. Perhaps the most 
important feature of pharmacological experiment is the double-blind placebo 
control.  In the experimental condition, participants receive the pharmacological 
agent; in the control condition, participants receive an inactive placebo. All 
aspects of the experimental procedure are identical aside from the administration 
of drug vs. placebo. Critically, neither the experimenter nor the participants know 
whether they have received drug or placebo. On the experimenter side, this is 
important so that the experimenter does not bias the data collection process, 
either consciously or unconsciously. On the participant side, this is important 
because beliefs about whether one has received drug or placebo can influence 
behavior independently from the effects of the drug itself (Eisenegger et al., 
2009). 
 Maintaining double-blind conditions can be difficult, however, when the 
pharmacological agent induces physical side effects such as nausea, increased 
heart rate, or dizziness, all of which are common symptoms of drugs typically 
used to manipulate neuromodulators, even at relatively low doses. Note that 
side-effects can be more severe in a neuroimaging environment. In addition to 
potentially interfering with task performance and producing subjective 
mood effects that could independently affect the dependent measures of 
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interest, side-effects also make it more likely that subjects will be able to 
distinguish between the drug and placebo. 
 One approach to this issue is to employ a positive control -- a second 
pharmacological agent used as a comparison condition for the drug of interest 
that has a similar side effect profile. For example, if one is interested in studying 
how serotonin influences social behavior, one could compare the effects of 
citalopram (a serotonin reuptake inhibitor) with those of atomoxetine (a 
noradrenaline reuptake inhibitor with a similar side effect profile to citalopram) as 
well as placebo (Crockett et al., 2010a). With this procedure, even if participants 
can distinguish between drug and placebo due to physical side effects, as long 
as they cannot distinguish between the experimental treatment (e.g., citalopram) 
and the positive control (e.g., atomoxetine), some degree of blindness can be 
maintained. Using a positive control has the additional benefit of probing for the 
neurochemical selectivity of the effect of inter st in terms of the neuromodulator 
systems involved in the process under examination.  
 
Controlling for beliefs 
 Even when one goes to great lengths to set up a double-blind placebo-
controlled procedure, participants may nevertheless form beliefs about which 
treatment they received that can significantly affect their behavior. It is therefore 
important to ask participants to report, at the end of the experiment, their 
subjective beliefs about which treatment they received. This belief data can be 
important: a notable example comes from a recent study examining the effects of 
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testosterone on bargaining behavior (Eisenegger et al., 2009). While 
testosterone caused participants to make more generous offers during a 
bargaining game, those subjects who believed they had received testosterone 
(as reported in the post-experiment questionnaire) made less generous offers, 
regardless of whether they actually received testosterone or placebo. The 
authors hypothesized that this belief effect reflects folk wisdom about 
testosterone: namely, that it causes antisocial or aggressive behavior. Thus, 
participants who believed they received testosterone may have felt 'morally 
licensed' to make less generous offers. This finding underscores the importance 
of measuring beliefs in these kinds of experiments, particularly when studying 
complex social interactions where beliefs can play a decisive role. 
 
Between-subjects versus within-subjects designs 
 In pharmacological studies, the drug treatment can be carried out either 
between subjects (in which one group of participants receives the 
pharmacological agent, and another matched group of participants receives 
placebo) or within subjects (in which participants take part in the experiment in 
multiple sessions, receiving placebo in one session and the drugs in the other 
sessions, with the order of treatments counterbalanced across participants). 
Each approach has advantages and disadvantages. Within-subjects designs 
tend to be more powerful statistically: because each participant serves as her 
own comparison, error variance associated with individual differences is reduced. 
This is particularly important in pharmacological experiments, because there are 
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several known genetic polymorphisms that influence the signaling properties 
within neuromodulator systems (e.g., the function of specific types of 
neuromodulator receptors).  These polymorphisms could create potentially 
large variation between individuals in terms of their physiological response to 
pharmacological treatment.  
 Within-subjects designs are less desirable when the behavior under study is 
susceptible to learning/practice effects or change across time, since subjects 
participate in the experiment multiple times. For example, Wood et al. (2006) 
used a within-subjects design to examine the effects of tryptophan 
depletion on behavior in a repeated prisoner’s dilemma, in which two 
players learn about each other’s propensity to cooperate or defect. 
Tryptophan depletion reduced cooperative behavior, but only on the first 
experimental session, i.e., when participants were naïve to the prisoner’s 
dilemma task and early in the process of l arning about the strategy of the 
other player. On the second experimental session, (after subjects had 
already learned the other player’s strategy), tryptophan depletion had little 
effect (Wood et al., 2006).  
 In addition, some social psychological paradigms are difficult (if not 
impossible) to conduct in a repeated-measures setting. In particular, those 
paradigms that involve deception pose a challenge for repeated-measures 
designs. Generally, when the research paradigm requires convincing 
subjects of something that is not true (e.g., subjects are led to believe that 
they are interacting with a real person, when in fact they are interacting 
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with a computer program), it is advisable to collect self-report measures at 
the end of the study to assess whether the subject believed the 
experimenter’s cover story. However, in a repeated-measures design, 
collecting self-report measures of belief in the cover story at the end of the 
first experimental session may contaminate behavior in the second 
experimental session, if the self-report measures raise suspicions about 
the veracity of the cover story where none were present before. To avoid 
this possibility, one might only collect belief measures at the end of the 
second session; however, this approach rests somewhat on the 
assumption that subjects’ beliefs about the veracity of the cover story are 
consistent across sessions and treatments, which may not be the case 
(see below, section ‘Demonstrating behavioral selectivity’). 
 If the aim of the experiment is to examine neuromodulator effects on 
learning or one-shot decisions, or in paradigms where within-subjects 
treatments are infeasible, a between-subjects design may be more appropriate. 
When using a between-subjects design, it is critical to ensure that the 
experimental group and the placebo group are matched on important 
characteristics such as sex, age, education, and perhaps also personality traits 
and genetic polymorphisms relevant to the neuromodulator system under study. 
While a detailed review of the effects of genetic polymorphisms beyond the 
scope of this review, it is worth mentioning that the effects of pharmacological 
manipulations can vary according to genotype (Eisenegger et al., 2010; Rogers, 
2010), an issue worth considering when designing pharmacological experiments, 
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especially those with between-subjects designs. 
 
Timing of drug administration 
 The time course of the effects of pharmacological manipulations varies 
depending on the agent used and the method of administration. Following oral 
administration of drugs, peak concentrations tend to occur within a few hours, 
while intravenous and intranasal administration tend to have faster-acting effects. 
Meanwhile, dietary depletions take considerably longer to exert their effects, on 
the order of 5-6 hours. It is important to precisely time the experimental 
procedure such that the dependent measures are collected at the time point most 
likely to coincide with peak drug effects.  
 If more than one pharmacological agent is used, and the drugs have 
different time-courses, a multiple-placebo procedure can be employed to 
maintain double-blind conditions. For exampl , consider a study comparing the 
effects of levodopa and citalopram with placebo, where levodopa reaches peak 
concentration 1 hour after administration, and citalopram reaches peak 
concentration 3 hours after administration. The levodopa group receives 
levodopa 1 hour prior to testing, and a placebo pill 3 hours prior to testing. The 
citalopram group receives placebo 1 hour prior to testing, and citalopram 3 hours 
prior to testing. Finally, the placebo group receives placebo at both 1 and 3 hours 
prior to testing. Thus, across conditions all subjects receive treatment at both 1hr 
and 3hr pretesting, but neither the subjects nor the experimenters know the 
contents of the treatment, maintaining double-blind conditions. 
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 Another consideration related to timing relates to experiments using within-
subjects designs. Drugs differ in the amount of time they take to leave the body. 
In within-subjects designs, it is important that testing sessions are spaced 
sufficiently far apart for a full washout to occur, generally at least one week. 
When recruiting subjects, it is also worth checking whether they have recently 
participated in other studies involving pharmacological manipulations. In addition, 
since other substances such as alcohol, caffeine, and recreational drugs can 
have prolonged effects in the brain and can interact with your experimental 
treatment, it is important to make sure subjects abstain from these substances 
for at least 24 hours prior to participation, and throughout the duration of the 
study (for within-subjects designs). 
 Finally, if females are included in the study, it is worth considering whether 
to control for menstrual phase cycle, since endogenous sex hormones could 
potentially interact with the neuromodulator under study. If this is a concern, it is 
good practice to restrict female participants to those with a regular menstrual 
cycle who are not taking oral contraceptives, and to t st them in the early 
follicular phase of the cycle, when the endogenous level of sex hormones tends 
to be low and stable.  
 
Choosing the appropriate dose 
 The chosen dose of the drug can have important implications for the effects 
of the manipulation. For example, low doses of sulpiride (a D2 antagonist; e.g., 
100-200mg) are thought to primarily exert effects on pre-synaptic receptors, 
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potentially leading to a net stimulatory effect on DA neurotransmission, while 
higher doses (e.g., 400-800mg) are more likely to act post-synaptically and 
reduce DA actions on D2 receptors (Di Giovanni et al., 1998). Meanwhile, low 
doses of SSRIs (e.g., 10mg) can reduce serotonin release by enhancing the 
actions of endogenous serotonin on pre-synaptic autoreceptors (Selvaraj et al., 
2012), whereas higher doses (e.g., 30mg and above) may be sufficient to 
enhance serotonin neurotransmission in terminal regions. In line with this idea, 
studies in animals have shown that different doses of SSRIs have different 
effects on motivated behavior (Bari et al., 2010). In humans, the effects of 
pharmacological manipulations at the molecular level are incompletely 
understood and should be interpreted with caution. Future studies combining 
pharmacological manipulations with positron emission tomography (PET) are 
needed to elucidate the effects of these manipulations on endogenous 
neurotransmitter synthesis and release. 
 
Blood plasma measures 
 As noted previously, there are widespread individual differences in 
physiological responses to pharmacological treatments. Collecting additional 
data from blood samples can provide information about the nature of these 
individual differences, and how they interact with the treatment. 
 When conducting precursor depletion studies, it is essential to collect blood 
samples both at baseline (i.e., before ingesting the amino acids) and just before 
testing. This enables confirmation that plasma levels of precursor, and the ratio 
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of precursor to LNAAs, were indeed depleted by the manipulation (Booij et al., 
2003), because the procedure can be compromised by participant non-
compliance (e.g., if the participant consumes any foods containing the 
precursor during the waiting period). Individual differences in plasma 
precursor levels can also serve as covariates in behavioral and neuroimaging 
analyses. For instance, individual differences in plasma tryptophan:LNAA ratios 
predicted individual differences in the effects of tryptophan depletion on impulsive 
choice behavior (Crockett et al., 2010b), and subject-specific plasma 
tryptophan:LNAA ratios influenced reward prediction error responses in the 
putamen (Seymour et al., 2012). 
 Unlike precursor depletion studies, drug or precursor administration 
studies do not necessarily require measurement of plasma levels of the 
drug, since these procedures are less vulnerable to participant non-
compliance. However, it can still be useful to collect blood samples to measure 
plasma levels of the drug, which sometimes covary with the drug’s behavioral 
and/or neural effects. For example, Chamberlain et al. (2009) found that plasma 
levels of atomoxetine predicted right inferior frontal gyrus activity during response 
inhibition (Chamberlain et al., 2009).  
 Note that for substances that cross the blood-brain barrier (e.g., tryptophan 
or atomoxetine), plasma levels of the substance are likely correlated with brain 
levels of that substance. However, for substances that have low penetration of 
the blood-brain barrier (e.g., oxytocin or vasopressin), plasma levels are not 
necessarily indicative of brain levels of that substance. Studies that use plasma 
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levels of a substance with weak penetration of the blood-brain barrier to make 
claims about brain levels of that substance should therefore be interpreted with 
caution (Churchland & Winkielman, 2012). 
 
Controlling for subjective experience 
 Because pharmacological manipulations can have physical side effects or 
influence mood more generally, it is important to rule out these factors as causal 
mediating forces in the effects of neuromodulators on social behavior. Subjective 
rating scales are a useful tool for assessing these effects. Commonly used 
scales include the Visual Analogue Scales (Bond & Lader, 1974) and the Positive 
and Negative Affect Scales (Watson et al., 1988). These scales assess the 
effects of the pharmacological manipulation on subjective feelings such as 
alertness, calmness, irritability, contentedness, drowsiness, anxiety, nausea, 
dizziness, and positive and negative affect. Drug-induced changes in physical 
side effects or mood can be included as regressors of no interest in statistical 
models capturing the effects of pharmacological manipulations on social 
behavior. 
 
Demonstrating behavioral selectivity 
 It is relatively straightforward to pick some behavior Z and perform a 
pharmacological study to examine the effects of neuromodulator X on behavior 
Z. However, to make the claim that X has a selective effect on Z requires some 
methodological sophistication. Because social behaviors are complex constructs 
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incorporating several more basic perceptual and motivational processes (many of 
which may be sensitive to the neuromodulator in question), to make claims about 
neuromodulators’ behavioral selectivity, one must control for these basic 
processes where possible. 
 An example of this comes from a study on how oxytocin affects behavior in 
a game of trust. In this study, oxytocin increased subjects’ trusting behavior by 
17%, relative to a placebo control group (Kosfeld et al., 2005). But before the 
authors could conclude that oxytocin modulates trust specifically, they had to rule 
out the possibility that oxytocin simply altered sensitivity to risk, as trust involves 
a degree of risk-taking. To do this, they conducted a risk experiment, in which 
subjects faced exactly the same decisions as in the trust game, but removed 
from a social context: the interaction partner was replaced with a computer. 
Critically, oxytocin did not affect behavior in the risk experiment, indicating that 
the effects of oxytocin on trust are specific to the social context. 
 Another issue worth considering is the possibility that 
neuromodulators may influence susceptibility to deception and/or 
experimenter demand effects. Oxytocin, for example, enhances trust in 
some settings (Van IJzendoorn & Bakermans-Kranenburg, 2012) and there 
is no a priori reason to assume that these effects do not extend to trust in 
the experimenter. Thus, paradigms in which experimenter demand effects 
are expected to be high, and/or those involving deception of subjects by 
the experimenters, may show an effect of oxytocin on the behavior of 
interest not because oxytocin actually influences the behavior of interest, 
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but because it enhances trust in the experimenter, and consequently, 
subjects’ engagement with the task. It is therefore critical to collect, where 
possible, independent measures of subjects’ beliefs about the veracity of 
the experimental set-up, engagement with the task, and desire to please the 
experimenter, in order to control for possible neuromodulator effects on 
these measures. 
 
Conclusion 
 One important challenge for human psychopharmacology is the scarcity of 
methods for assessing the molecular-level effects of pharmacological 
manipulations in vivo. While it is straightforward to investigate how drug 
treatments alter behavior and brain hemodynamic responses, these measures 
reflect downstream effects of the changes in neurotransmission at the molecular 
level. Previous pharmacological studies in humans provide evidence of 
behavioral effects, but can say very little about the underlying changes in 
neurotransmission. Positron emission tomography (PET) imaging can provide 
quantitative measurements of endogenous neurotransmitter release (Martinez et 
al., 2003; Selvaraj et al., 2012); future studies could combine pharmacological 
manipulations with PET, fMRI and behavioral measurements to link the drug 
treatment to changes in endogenous neurotransmitter release to changes in 
neural activity to changes in behavior. 
 As social neuroscience progresses, it will become ever more important to 
employ methods that enable inferences about cause and effect. The combination 
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of pharmacological manipulations with neuroimaging will facilitate the 
identification of the brain networks that are causally involved in generating social 
cognition and behavior. These kinds of studies will bring us closer to a 
mechanistic understanding of social interaction.  
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